IGF-1 has sexually dimorphic, pleiotropic, and time-dependent effects on healthspan, pathology, and lifespan
Tóm tắt
Reduced circulating levels of IGF-1 have been proposed as a conserved anti-aging mechanism that contributes to increased lifespan in diverse experimental models. However, IGF-1 has also been shown to be essential for normal development and the maintenance of tissue function late into the lifespan. These disparate findings suggest that IGF-1 may be a pleiotropic modulator of health and aging, as reductions in IGF-1 may be beneficial for one aspect of aging, but detrimental for another. We postulated that the effects of IGF-1 on tissue health and function in advanced age are dependent on the tissue, the sex of the animal, and the age at which IGF-1 is manipulated. In this study, we examined how alterations in IGF-1 levels at multiple stages of development and aging influence overall lifespan, healthspan, and pathology. Specifically, we investigated the effects of perinatal, post-pubertal, and late-adult onset IGF-1 deficiency using genetic and viral approaches in both male and female igf
f/f
C57Bl/6 mice. Our results support the concept that IGF-1 levels early during lifespan establish the conditions necessary for subsequent healthspan and pathological changes that contribute to aging. Nevertheless, these changes are specific for each sex and tissue. Importantly, late-life IGF-1 deficiency (a time point relevant for human studies) reduces cancer risk but does not increase lifespan. Overall, our results indicate that the levels of IGF-1 during development influence late-life pathology, suggesting that IGF-1 is a developmental driver of healthspan, pathology, and lifespan.
Tài liệu tham khảo
Amato G et al (1993) Body composition, bone metabolism, and heart structure and function in growth hormone (GH)-deficient adults before and after GH replacement therapy at low doses. J Clin Endocrinol Metab 77:1671–1676. doi:10.1210/jcem.77.6.8263158
Arum O, Rickman DJ, Kopchick JJ, Bartke A (2014) The slow-aging growth hormone receptor/binding protein gene-disrupted (GHR-KO) mouse is protected from aging-resultant neuromusculoskeletal frailty. Age 36:117–127. doi:10.1007/s11357-013-9551-x
Ashpole NM et al (2015) IGF-1 regulates vertebral bone aging through sex-specific and time-dependent mechanisms. J Bone Miner Res Off J Am Soc Bone Miner Res. doi:10.1002/jbmr.2689
Ashpole NM et al (2016a) Differential effects of IGF-1 deficiency during the life span on structural and biomechanical properties in the tibia of aged mice. Age 38:38. doi:10.1007/s11357-016-9902-5
Ashpole NM et al (2016b) IGF-1 regulates vertebral Bone aging through sex-specific and time-dependent mechanisms. J Bone Miner Res Off J Am Soc Bone Miner Res 31:443–454. doi:10.1002/jbmr.2689
Austad SN, Fischer KE (2016) Sex differences in lifespan. Cell Metab 23:1022–1033. doi:10.1016/j.cmet.2016.05.019
Bailey-Downs LC et al (2012a) Liver-specific knockdown of IGF-1 decreases vascular oxidative stress resistance by impairing the Nrf2-dependent antioxidant response: a novel model of vascular aging. J Gerontol A Biol Sci Med Sci 67:313–329. doi:10.1093/gerona/glr164
Bailey-Downs LC et al (2012b) Growth hormone and IGF-1 deficiency exacerbate high-fat diet-induced endothelial impairment in obese Lewis dwarf rats: implications for vascular aging. J Gerontol A Biol Sci Med Sci 67:553–564. doi:10.1093/gerona/glr197
Bansal A, Zhu LJ, Yen K, Tissenbaum HA (2015) Uncoupling lifespan and healthspan in Caenorhabditis elegans longevity mutants. Proc Natl Acad Sci U S A 112:E277–E286. doi:10.1073/pnas.1412192112
Bartke A, Brown-Borg H (2004) Life extension in the dwarf mouse. Curr Top Dev Biol 63:189–225. doi:10.1016/S0070-2153(04)63006-7
Bartke A et al (2000) Growth hormone and aging. Journal of the American Aging Association 23:219–225. doi:10.1007/s11357-000-0021-x
Bokov AF et al. (2011) Does reduced IGF-1R signaling in Igf1r(+/−) mice alter aging? Plos ONE 6:e26891. doi:10.1371/journal.pone.0026891
Bronson RT, Lipman RD (1993) The role of pathology in rodent experimental gerontology. Aging-Clin Exp Res 5:253–257
Brown-Borg HM (2015) The somatotropic axis and longevity in mice. Am J Phys Endocrinol Metab 309:E503–E510. doi:10.1152/ajpendo.00262.2015
Brown-Borg HM, Borg KE, Meliska CJ, Bartke A (1996) Dwarf mice and the ageing process. Nature 384:33. doi:10.1038/384033a0
Coschigano KT, Clemmons D, Bellush LL, Kopchick JJ (2000) Assessment of growth parameters and life span of GHR/BP gene-disrupted mice. Endocrinology 141:2608–2613. doi:10.1210/endo.141.7.7586
Coschigano KT, Holland AN, Riders ME, List EO, Flyvbjerg A, Kopchick JJ (2003) Deletion, but not antagonism, of the mouse growth hormone receptor results in severely decreased body weights, insulin, and insulin-like growth factor I levels and increased life span. Endocrinology 144:3799–3810. doi:10.1210/en.2003-0374
De Boer H, Blok GJ, Voerman HJ, De Vries PM, van der Veen EA (1992) Body composition in adult growth hormone-deficient men, assessed by anthropometry and bioimpedance analysis. J Clin Endocrinol Metab 75:833–837. doi:10.1210/jcem.75.3.1517374
Eriksson JG, Forsen TJ, Kajantie E, Osmond C, Barker DJ (2007) Childhood growth and hypertension in later life. Hypertension 49:1415–1421. doi:10.1161/HYPERTENSIONAHA.106.085597
Eriksson JG, Forsen T, Tuomilehto J, Winter PD, Osmond C, Barker DJ (1999) Catch-up growth in childhood and death from coronary heart disease: longitudinal study. BMJ 318:427–431
Gong Z et al (2014) Reductions in serum IGF-1 during aging impair health span. Aging Cell 13:408–418. doi:10.1111/acel.12188
Harrison DE et al (2014) Acarbose, 17-alpha-estradiol, and nordihydroguaiaretic acid extend mouse lifespan preferentially in males. Aging Cell 13:273–282. doi:10.1111/acel.12170
Hascup KN et al (2016) Enhanced cognition and hypoglutamatergic signaling in a growth hormone receptor knockout mouse model of successful aging. J Gerontol A Biol Sci Med Sci. doi:10.1093/gerona/glw088
Herenu CB, Cristina C, Rimoldi OJ, Becu-Villalobos D, Cambiaggi V, Portiansky EL, Goya RG (2007) Restorative effect of insulin-like growth factor-I gene therapy in the hypothalamus of senile rats with dopaminergic dysfunction. Gene Ther 14:237–245. doi:10.1038/sj.gt.3302870
Holzenberger M et al (2003) IGF-1 receptor regulates lifespan and resistance to oxidative stress in mice. Nature 421:182–187. doi:10.1038/nature01298
Ikeno Y, Bronson RT, Hubbard GB, Lee S, Bartke A (2003) Delayed occurrence of fatal neoplastic diseases in Ames dwarf mice: correlation to extended longevity. J Gerontol a-Biol 58:291–296
Ikeno Y, Hubbard GB, Lee S, Richardson A, Strong R, Diaz V, Nelson JF (2005) Housing density does not influence the longevity effect of calorie restriction. J Gerontol a-Biol 60:1510–1517
Ikeno Y et al (2009) Reduced incidence and delayed occurrence of fatal neoplastic diseases in growth hormone receptor/binding protein knockout mice. J Gerontol A Biol Sci Med Sci 64:522–529. doi:10.1093/gerona/glp017
Johansson JO, Fowelin J, Landin K, Lager I, Bengtsson BA (1995) Growth hormone-deficient adults are insulin-resistant. Metab Clin Exp 44:1126–1129
Kajantie E, Osmond C, Barker DJ, Forsen T, Phillips DI, Eriksson JG (2005) Size at birth as a predictor of mortality in adulthood: a follow-up of 350 000 person-years. Int J Epidemiol 34:655–663. doi:10.1093/ije/dyi048
Koenker R (2008) Censored quantile regression redux. J Stat Softw 27:1–25
Ladiges W, Van Remmen H, Strong R, Ikeno Y, Treuting P, Rabinovitch P, Richardson A (2009) Lifespan extension in genetically modified mice. Aging Cell 8:346–352. doi:10.1111/j.1474-9726.2009.00491.x
Markowska AL, Mooney M, Sonntag WE (1998) Insulin-like growth factor-1 ameliorates age-related behavioral deficits. Neuroscience 87:559–569
Merola B et al (1993) Cardiac structural and functional abnormalities in adult patients with growth hormone deficiency. J Clin Endocrinol Metab 77:1658–1661. doi:10.1210/jcem.77.6.8263155
Miller RA et al (2007) An Aging Interventions Testing Program: study design and interim report. Aging Cell 6:565–575. doi:10.1111/j.1474-9726.2007.00311.x
Miller RA et al (2011) Rapamycin, but not resveratrol or simvastatin, extends life span of genetically heterogeneous mice. J Gerontol A Biol Sci Med Sci 66:191–201. doi:10.1093/gerona/glq178
Miller RA et al (2014) Rapamycin-mediated lifespan increase in mice is dose and sex dependent and metabolically distinct from dietary restriction. Aging Cell 13:468–477. doi:10.1111/acel.12194
Milman S, Atzmon G, Huffman DM, Wan J, Crandall JP, Cohen P, Barzilai N (2014) Low insulin-like growth factor-1 level predicts survival in humans with exceptional longevity. Aging Cell 13:769–771. doi:10.1111/acel.12213
Osmond C, Kajantie E, Forsen TJ, Eriksson JG, Barker DJ (2007) Infant growth and stroke in adult life: the Helsinki birth cohort study. Stroke; a journal of cerebral circulation 38:264–270. doi:10.1161/01.STR.0000254471.72186.03
Podlutsky A et al (2017) The GH/IGF-1 axis in a critical period early in life determines cellular DNA repair capacity by altering transcriptional regulation of DNA repair-related genes: implications for the developmental origins of cancer. Geroscience. doi:10.1007/s11357-017-9966-x
Radaelli E, Arnold A, Papanikolaou A, Garcia-Fernandez RA, Mattiello S, Scanziani E, Cardiff RD (2009) Mammary tumor phenotypes in wild-type aging female FVB/N mice with pituitary prolactinomas. Vet Pathol 46:736–745. doi:10.1354/vp.08-VP-0280-R-FL
Ramsey MM, Weiner JL, Moore TP, Carter CS, Sonntag WE (2004) Growth hormone treatment attenuates age-related changes in hippocampal short-term plasticity and spatial learning. Neuroscience 129:119–127. doi:10.1016/j.neuroscience.2004.08.001
Richardson A, Liu F, Adamo ML, Van Remmen H, Nelson JF (2004) The role of insulin and insulin-like growth factor-I in mammalian ageing. Best Pract Res Clin Endocrinol Metab 18:393–406. doi:10.1016/j.beem.2004.02.002
Rincon M, Rudin E, Barzilai N (2005) The insulin/IGF-1 signaling in mammals and its relevance to human longevity. Exp Gerontol 40:873–877. doi:10.1016/j.exger.2005.06.014
Sonntag WE, Csiszar A, deCabo R, Ferrucci L, Ungvari Z (2012) Diverse roles of growth hormone and insulin-like growth factor-1 in mammalian aging: progress and controversies. J Gerontol A Biol Sci Med Sci 67:587–598. doi:10.1093/gerona/gls115
Sonntag WE, Lynch CD, Cefalu WT, Ingram RL, Bennett SA, Thornton PL, Khan AS (1999) Pleiotropic effects of growth hormone and insulin-like growth factor (IGF)-1 on biological aging: inferences from moderate caloric-restricted animals. J Gerontol A Biol Sci Med Sci 54:B521–B538
Sonntag WE, Lynch C, Thornton P, Khan A, Bennett S, Ingram R (2000) The effects of growth hormone and IGF-1 deficiency on cerebrovascular and brain ageing. J Anat 197(Pt 4):575–585
Sonntag WE et al (2005) Adult-onset growth hormone and insulin-like growth factor I deficiency reduces neoplastic disease, modifies age-related pathology, and increases life span. Endocrinology 146:2920–2932. doi:10.1210/en.2005-0058
Suh Y et al (2008) Functionally significant insulin-like growth factor I receptor mutations in centenarians. Proc Natl Acad Sci U S A 105:3438–3442. doi:10.1073/pnas.0705467105
Toth P et al (2014) IGF-1 deficiency impairs cerebral myogenic autoregulation in hypertensive mice. Journal of cerebral blood flow and metabolism: official journal of the International Society of Cerebral Blood Flow and Metabolism 34:1887–1897. doi:10.1038/jcbfm.2014.156
Toth P et al (2015) IGF-1 deficiency impairs neurovascular coupling in mice: implications for cerebromicrovascular aging. Aging Cell. doi:10.1111/acel.12372
van Dam PS et al (2005) Childhood-onset growth hormone deficiency, cognitive function and brain N-acetylaspartate. Psychoneuroendocrinology 30:357–363. doi:10.1016/j.psyneuen.2004.10.002
van Heemst D et al (2005) Reduced insulin/IGF-1 signalling and human longevity. Aging Cell 4:79–85. doi:10.1111/j.1474-9728.2005.00148.x
Xu J, Gontier G, Chaker Z, Lacube P, Dupont J, Holzenberger M (2014) Longevity effect of IGF-1R(+/−) mutation depends on genetic background-specific receptor activation. Aging Cell 13:19–28. doi:10.1111/acel.12145
Yakar S, Liu JL, Stannard B, Butler A, Accili D, Sauer B, LeRoith D (1999) Normal growth and development in the absence of hepatic insulin-like growth factor I. Proc Natl Acad Sci U S A 96:7324–7329